Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia
Conditions
Interventions
Tenapanor
Placebo
+1 more
Locations
48
United States
Nephrology Consultants, LLC
Huntsville, Alabama, United States
US Renal Care Pine Bluff
Pine Bluff, Arkansas, United States
Southeast Renal Research
Beverly Hills, California, United States
California Institute of Renal Research - Chula Vista
Chula Vista, California, United States
North America Research Institute
Lynwood, California, United States
DaVita Clinical Research - Santa Fe Spring
Montebello, California, United States
Start Date
February 28, 2019
Primary Completion Date
July 17, 2019
Completion Date
July 17, 2019
Last Updated
March 6, 2023
NCT06933472
NCT03573089
NCT00506441
NCT00542815
NCT05085275
NCT04456803
Lead Sponsor
Ardelyx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions